skip to Main Content

Cost-Effectiveness Analysis of Adjuvant Treatment for Resected Pancreatic Cancer in China Based on the ESPAC-4 Trial

Newsfeed image, light gray text on dark gray background
The effectiveness of gemcitabine plus capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer has been evaluated in the ESPAC-4 trial.

We aimed to assess the cost-effectiveness of these adjuvant regimens on resected pancreatic cancer. Read more . . . 

Back To Top